Previous Close | 4.0000 |
Open | 4.0300 |
Bid | 4.0900 x 800 |
Ask | 4.1200 x 800 |
Day's Range | 3.9600 - 4.1950 |
52 Week Range | 1.7900 - 7.4500 |
Volume | |
Avg. Volume | 1,856,227 |
Market Cap | 1.093B |
Beta (5Y Monthly) | 1.93 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.2000 |
Earnings Date | May 14, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10.69 |
Autolus Therapeutics plc ( NASDAQ:AUTL ) shareholders might be rather concerned because the share price has dropped 33...
LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract for longer-term follow-up and additional data analysis from the pivotal Phase 2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) was selected for an oral presentation at the 2024 American Society of Clinica
LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2024 financial results and operational highlights before open of US markets on Tuesday, May 14, 2024. Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the company’s financial results and provide a general business update.